Benowitz N L, Fitzgerald G A, Wilson M, Zhang Q
Division of Clinical Pharmacology and Experimental Therapeutics, San Francisco General Hospital Medical Center, California 94110.
J Am Coll Cardiol. 1993 Oct;22(4):1159-67. doi: 10.1016/0735-1097(93)90431-y.
The purpose of this study was to examine the possible role of nicotine in enhancing coagulation and to assess the potential cardiovascular toxicity of transdermal nicotine therapy for smoking cessation.
Cigarette smoking increases the risks of acute coronary events. A likely contributing mechanism is activation of coagulation. The role of nicotine in enhancing coagulability has not been resolved.
We compared in a crossover study the effects of cigarette smoking, transdermal nicotine and placebo transdermal nicotine, each for 5 days, in 12 healthy smokers.
Cigarette smoking increased the urinary excretion of 11-dehydro-thromboxane B2 (reflecting thromboxane A2 generation) and increased plasma concentration of the platelet alpha-granule constituents, platelet factor 4 and beta-thromboglobulin, compared with placebo treatment, indicating in vivo platelet activation. Cigarette smoking was also associated with higher levels of fibrinogen in plasma. Transdermal nicotine produced plasma levels of nicotine in the same range as those during smoking but had no effect on thromboxane A2 metabolite excretion, platelet alpha-granule release or plasma fibrinogen, compared with placebo. Excretion of 2,3-dinor-6-keto-PGF1 alpha (reflecting prostacyclin generation) was not significantly influenced by any treatment. These results suggest that nicotine as such is not responsible for the platelet activation or elevation of plasma fibrinogen seen in smokers. However, we cannot exclude the possibility that intermittent bolus-like dosing of nicotine from cigarettes could have different effects from those produced by continually released transdermal nicotine. Other findings were that cigarette smoking and transdermal nicotine treatment were both associated with a higher white blood cell count compared with the placebo patch condition, suggesting a direct effect of nicotine to increase circulating white cells. Factor VII coagulant activity (VIIc) was significantly lower during cigarette smoking, than during either nicotine or placebo patch conditions.
Transdermal nicotine has less effect on platelet activation and catecholamine release than does cigarette smoking, and its use in smoking cessation treatment of patients with coronary heart disease is likely to be safer than cigarette smoking.
本研究旨在探讨尼古丁在增强凝血方面可能发挥的作用,并评估经皮尼古丁疗法用于戒烟时潜在的心血管毒性。
吸烟会增加急性冠脉事件的风险。一个可能的促成机制是凝血激活。尼古丁在增强凝血性方面的作用尚未明确。
我们在一项交叉研究中比较了吸烟、经皮尼古丁和安慰剂经皮尼古丁对12名健康吸烟者的影响,每种干预持续5天。
与安慰剂治疗相比,吸烟增加了11-脱氢血栓素B2的尿排泄量(反映血栓素A2生成),并提高了血小板α颗粒成分、血小板因子4和β-血小板球蛋白的血浆浓度,表明体内血小板被激活。吸烟还与血浆中较高水平的纤维蛋白原有关。经皮尼古丁产生的血浆尼古丁水平与吸烟时相同,但与安慰剂相比,对血栓素A2代谢物排泄、血小板α颗粒释放或血浆纤维蛋白原没有影响。2,3-二去甲-6-酮-前列环素F1α的排泄(反映前列环素生成)不受任何治疗的显著影响。这些结果表明,尼古丁本身并非导致吸烟者血小板激活或血浆纤维蛋白原升高的原因。然而,我们不能排除香烟中尼古丁的间歇性大剂量给药可能产生与持续释放的经皮尼古丁不同的效果。其他发现是,与安慰剂贴片情况相比吸烟和经皮尼古丁治疗均与较高的白细胞计数有关,表明尼古丁对增加循环白细胞有直接作用。吸烟期间的因子VII凝血活性(VIIc)显著低于尼古丁或安慰剂贴片情况。
与吸烟相比,经皮尼古丁对血小板激活和儿茶酚胺释放的影响较小,在冠心病患者的戒烟治疗中使用经皮尼古丁可能比吸烟更安全。